The head of Teva, the world’s biggest generic drugs company, is seeking to forge a joint venture in Japan to increase its market share of one of the world’s largest medicines markets.

Shlomo Yanai, chief executive, told the Financial Times that capitalising on Japan’s small but fast-growing market for generic medicines was a top priority, even just after concluding the $7.5bn acquisition of Barr of the US this month.